Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
PURPOSE: This review discusses the role of bacterial adjuvants and antigens in induction and reactivation of chronic intestinal inflammation in susceptible hosts; discusses the results of recent therapeutic trials of antibiotics, probiotics, and prebiotics; and suggests future treatment strategies. RECENT FINDINGS: Bacterial adjuvants, including peptidoglycan, lipopolysaccharide, and DNA (CpG) bind to membrane-bound toll-like receptors (TLR-2, 4, and 9. respectively) or cytoplasmic (NOD1 and NOD2) receptors (pattern recognition receptors) that activate nuclear factor-kappaB and transcription of many proinflammatory cytokines and adhesion, costimulatory, and major histocompatibility complex class II molecules. Experimental enterocolitis does not occur in a sterile (germ-free) environment and is prevented and treated by broad-spectrum antibiotics. Individual nonpathogenic intestinal bacterial species selectively induce experimental colitis, with host specificity. Crohn disease and ulcerative colitis patients exhibit pathogenic immune responses (loss of immunologic tolerance) to multiple normal enteric bacterial species and serologic responses to Mycobacterium paratuberculosis. Metronidazole and ciprofloxacin selectively treat colonic Crohn disease, but not ulcerative colitis or ileal Crohn disease, and may prevent recurrence of postoperative Crohn disease. Certain probiotic species decrease relapse of ulcerative colitis and chronic pouchitis and delay onset of pouchitis. SUMMARY: Normal, nonpathogenic enteric bacteria induce and perpetuate chronic intestinal inflammation in genetically susceptible hosts with defective immunoregulation, bacterial clearance, or mucosal barrier function. Altering the composition and decreasing mucosal adherence/invasion of commensal bacteria with antibiotics, probiotics, and prebiotics can potentially prevent and treat Crohn disease, pouchitis, and possibly ulcerative colitis, but optimal treatments have not yet been identified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sellon, R. K., Tonkonogy, S., Schultz, M., Dieleman, L. A., Grenther, W., Balish, E., Rennick, D. M., & Sartor, R. B. (1998) · Infection and Immunity · doi:10.1128/iai.66.11.5224-5231.1998 · Cited by 1,483
Self-citationDietary Inulin Improves Distal Colitis Induced by Dextran Sodium Sulfate in the Rat
Videla, S., Vilaseca, J., Antolín, M., García-Lafuente, A., Guarner, F., Crespo, E., Casalots, J., Salas, A., & Malagelada, J. R. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03802.x · Cited by 209
Cited by
Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach
Manichanh, C., Rigottier-Gois, L., Bonnaud, E., Gloux, K., Pelletier, E., Frangeul, L., Nalin, R., Jarrin, C., Chardon, P., Marteau, P., et al. (2006) · Gut · doi:10.1136/gut.2005.073817 · Cited by 2,277
Molecular analysis of the gut microbiota of identical twins with Crohn's disease
Dicksved, J., Halfvarson, J., Rosenquist, M., Järnerot, G., Tysk, C., Apajalahti, J., Engstrand, L., & Jansson, J. K. (2008) · The ISME Journal · doi:10.1038/ismej.2008.37 · Cited by 459
Zyrek, A. A., Cichon, C., Helms, S., Enders, C., Sonnenborn, U., & Schmidt, M. A. (2007) · Cellular Microbiology · doi:10.1111/j.1462-5822.2006.00836.x · Cited by 428
The dual role of bacteriocins as anti- and probiotics
Gillor, O., Etzion, A., & Riley, M. A. (2008) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-008-1726-5 · Cited by 416
The love–hate relationship between bacterial polysaccharides and the host immune system
Mazmanian, S. K., & Kasper, D. L. (2006) · Nature Reviews Immunology · doi:10.1038/nri1956 · Cited by 356
Metadata
- Authors
- Sartor, B. R.
- Venue
- Current Opinion in Gastroenterology
- Published
- 2003-07
- Volume
- 19
- Issue
- 4
- Pages
- 358-365
- ISSN
- 0267-1379 (ISSN-L)
- OpenAlex
- W2120087747
- Cited by
- 93
- References
- 2
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when. https://app.cochat.ai/papers/10.1097/00001574-200307000-00006
- The paper
- Sartor, B. R. (2003). Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when. Current Opinion in Gastroenterology. https://doi.org/10.1097/00001574-200307000-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.